How should I reconstitute 36 mg of Retatrutide to achieve a concentration of 12 mg/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Reconstitution of Retatrutide to 12 mg/mL

To achieve a concentration of 12 mg/mL from 36 mg of Retatrutide, add 3 mL of bacteriostatic water for injection to the vial.

Calculation Method

  • Using the basic formula: Final Volume (mL) = Total Drug Amount (mg) ÷ Desired Concentration (mg/mL), you need 36 mg ÷ 12 mg/mL = 3 mL of diluent 1

  • This calculation follows the same mathematical principles used for reconstituting other injectable medications, such as vecuronium (10 mg reconstituted with 10 mL normal saline to achieve 1 mg/mL) 2

Step-by-Step Reconstitution Protocol

  • Gather sterile supplies including the 36 mg Retatrutide vial, 3 mL bacteriostatic water for injection, alcohol swabs, and appropriate syringes under aseptic technique 1

  • Inject 3 mL of bacteriostatic water slowly into the vial, directing the stream against the vial wall rather than directly onto the lyophilized powder to minimize foaming 1

  • Gently swirl the vial (do not shake vigorously) until the powder is completely dissolved and the solution appears clear; this typically takes 1-2 minutes 1

  • Inspect the reconstituted solution for particulate matter and discoloration before use; the solution should be clear and colorless 1

  • Label the vial clearly with the final concentration (12 mg/mL), date and time of reconstitution, and your initials 1

Storage and Stability Considerations

  • Refrigerate the reconstituted solution at 2-8°C (36-46°F) immediately after preparation; based on peptide stability data for similar GLP-1 receptor agonists, reconstituted Retatrutide should remain stable for up to 28 days when properly refrigerated 3, 4

  • Protect from light by storing in the original carton or wrapping the vial in aluminum foil, as peptide medications are typically photosensitive 3, 4

  • Allow to reach room temperature (15-20 minutes) before each injection to minimize injection site discomfort 3, 4

Dosing Verification

  • At 12 mg/mL concentration, common Retatrutide doses translate to specific volumes: 4 mg = 0.33 mL, 8 mg = 0.67 mL, and 12 mg = 1.0 mL 3, 4

  • Use an insulin syringe or tuberculin syringe for accurate measurement of small volumes, as dosing precision is critical for peptide medications 3, 4

Critical Safety Considerations

  • Never use normal saline or sterile water without preservative for multi-dose vials, as bacteriostatic water contains 0.9% benzyl alcohol to prevent bacterial contamination over multiple uses 1

  • Discard any unused solution after 28 days even if refrigerated, as peptide degradation and loss of sterility become concerns beyond this timeframe 3, 4

  • Do not mix Retatrutide with other medications in the same syringe, as compatibility data is not available and co-administration may affect stability 3, 4

Related Questions

How do I administer a 2 mg dose of Retatrutide from a 12 mg vial?
Can retatrutide (dual GLP-1 (Glucagon-Like Peptide-1) and glucagon receptor agonist) decrease visceral adiposity?
How much bacteriostatic water should be added to a 10 mg vial of retatrutide to achieve a concentration of 10 mg/mL?
What is the optimal micro‑dosing protocol for retatrutide?
Is it safe to administer a 2mg shot of Retatrutide (generic name) twice a week to a 208lb male?
What medications and dosing should be used to control intracranial pressure, provide sedation, prevent seizures, prophylax deep vein thrombosis, and manage blood pressure in a patient with a massive cerebral infarct causing significant edema and mass effect?
What does low follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) indicate in women?
Is the inpatient and outpatient diabetes management guideline you provided based on the latest American Diabetes Association Standards of Care (2024/2025)?
What is the recommended management for chronic fatigue syndrome (myalgic encephalomyelitis)?
What is an enteric fistula and could green drainage from a Jackson‑Pratt drain after ventral or incisional hernia repair with mesh indicate its presence?
In a 40‑year‑old male with major depressive disorder, generalized anxiety disorder, adjustment disorder, attention‑deficit/hyperactivity disorder, chronic nicotine and marijuana use, hypertension, benign prostatic hyperplasia, obstructive sleep apnea (adherent to CPAP), and shift‑work sleep disorder, currently on escitalopram 10 mg daily, propranolol 120 mg extended‑release, tamsulosin 0.4 mg, and recently started Adderall (amphetamine‑dextroamphetamine) XR 10 mg, who refuses any medication changes despite fatigue on dose increase, reports irritability, occasional spending sprees, and a positive Mood Disorder Questionnaire but does not meet full DSM‑5 bipolar criteria, how can I further evaluate for bipolar disorder and what management steps are appropriate given his medication refusal and functional impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.